Haemonetics Co. (HAE) Given Average Recommendation of “Buy” by Analysts

Shares of Haemonetics Co. (NYSE:HAE) have earned a consensus rating of “Buy” from the seven brokerages that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $117.75.

A number of equities analysts have recently commented on the stock. Zacks Investment Research raised shares of Haemonetics from a “sell” rating to a “hold” rating in a report on Tuesday, April 9th. ValuEngine cut shares of Haemonetics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 5th. Raymond James raised shares of Haemonetics from a “market perform” rating to an “outperform” rating and set a $110.00 price objective on the stock in a research note on Tuesday, May 14th. Barrington Research boosted their price objective on shares of Haemonetics to $112.00 and gave the company a “positive” rating in a research note on Wednesday, February 6th. Finally, TheStreet raised shares of Haemonetics from a “c+” rating to a “b-” rating in a research note on Tuesday, May 7th.

Shares of Haemonetics stock traded up $1.96 during trading on Friday, reaching $101.01. The company’s stock had a trading volume of 248,387 shares, compared to its average volume of 483,001. The stock has a market capitalization of $5.16 billion, a price-to-earnings ratio of 42.26, a PEG ratio of 2.56 and a beta of 0.85. Haemonetics has a fifty-two week low of $80.24 and a fifty-two week high of $117.56. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.44 and a quick ratio of 1.62.



Haemonetics (NYSE:HAE) last announced its earnings results on Tuesday, May 7th. The medical instruments supplier reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.06. The business had revenue of $249.30 million for the quarter, compared to analysts’ expectations of $250.62 million. Haemonetics had a net margin of 5.69% and a return on equity of 18.88%. The company’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.43 EPS. Analysts anticipate that Haemonetics will post 2.93 earnings per share for the current year.

In other Haemonetics news, EVP Michelle L. Basil sold 391 shares of the business’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $83.57, for a total value of $32,675.87. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Christopher Simon sold 57,587 shares of the business’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $94.51, for a total transaction of $5,442,547.37. The disclosure for this sale can be found here. Insiders sold a total of 87,220 shares of company stock worth $8,347,039 over the last three months. 1.04% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in HAE. Wellington Management Group LLP increased its stake in Haemonetics by 20.0% in the 1st quarter. Wellington Management Group LLP now owns 5,935,913 shares of the medical instruments supplier’s stock valued at $519,273,000 after buying an additional 988,179 shares during the period. Norges Bank purchased a new stake in shares of Haemonetics during the 4th quarter worth $80,411,000. Westfield Capital Management Co. LP boosted its position in shares of Haemonetics by 144.3% during the 4th quarter. Westfield Capital Management Co. LP now owns 709,952 shares of the medical instruments supplier’s stock worth $71,031,000 after purchasing an additional 419,359 shares in the last quarter. BlackRock Inc. boosted its position in shares of Haemonetics by 5.9% during the 1st quarter. BlackRock Inc. now owns 6,385,237 shares of the medical instruments supplier’s stock worth $558,580,000 after purchasing an additional 358,431 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of Haemonetics by 24.8% during the 1st quarter. AQR Capital Management LLC now owns 1,083,510 shares of the medical instruments supplier’s stock worth $94,785,000 after purchasing an additional 215,054 shares in the last quarter. 96.61% of the stock is currently owned by institutional investors.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Featured Article: Growth and Income Funds

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.